Comparison of two pediatric cases requiring the use of bivalirudin during cardiopulmonary bypass
Bryant ME, Regan WL, Fynn-Thompson F, Hoganson D, Nasr VG, Zaleski K, Faella K, Matte GS (2018) · Perfusion · n=2
Studienprofil
- Design
- case comparison of two pediatric cardiopulmonary bypass cases (bilateral lung transplant and ventricular assist device implantation) using identical bivalirudin protocol
- Stichprobengröße (n)
- 2
- Intervention
- Bivalirudin 1 mg/kg bolus + 50 mg pump prime + 2.5 mg/kg/h infusion titrated to K-ACT >400s during CPB
- Komparator
- Same protocol comparison between BLT and VAD implantation
- Primärer Endpunkt
- K-ACT achievement and dose titration requirements during pediatric CPB
- Primäres Ergebnis
- BLT case maintained K-ACT >720s despite reducing infusion to 0.5 mg/kg/h; VAD case required infusion increase to 5.0 mg/kg/h for low K-ACTs; both cases successful but highlight dose variability
- Follow-up-Dauer
- CPB run duration
- PMID
- 29638202
Wichtigste Ergebnisse
- 10-fold variability in bivalirudin dose requirements between two pediatric CPB cases
- BLT case over-anticoagulated, VAD case required dose escalation
- Same starting protocol but dramatically different titration needed
- Recommends minimum infusion of 0.5 mg/kg/h
- One-page timeline protocol shared for adoption
Einschränkungen
- Only 2 cases - case comparison not generalizable
- Single-center experience
- Heterogeneous clinical scenarios (transplant vs VAD)
- K-ACT not validated against direct bivalirudin levels
- Not applicable to whole-leech hirudotherapy
Klinische Implikationen
Bryant 2018 documents extreme inter-patient dose variability in pediatric CPB bivalirudin use, motivating individualized monitoring protocols. For ASH, this Boston Children's case comparison illustrates how the synthetic thrombin inhibitor pharmaceutical pathway requires substantial institutional protocolization, distinct from the K040187 device-leech US clinical practice where dose-equivalent considerations are clinically simpler (number and duration of leech sessions).
Verwandte Studien
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation
McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)
Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support
Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)
Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation
Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022)
Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review
Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)